Reducing Cancer Care Costs and Hospital Stays

There are two really irritating things about cancer care for me. (Well there are really lots of things that irritate me about cancer care. I could make a giant list of them if anyone really cared but today I am going to focus on two things.Cancer care is ridiculously expensive. You can take a drug for $100,000 that might increase your lifespan for a couple of months. A single chemo infusion can cost upwards of $20,000.And at the least sign of germs or low blood counts, you are sent to the emergency room where they admit you. That is a really stupid part. You feel like crap on a Friday night, you call your oncologist and they send you to the emergency room for blood tests and then they admit you after you sit in a room full of car accident victims and finally end up in a really uncomfortable bed with IV antibiotics. Really not a good idea.The second annoying issue is how quickly doctors throw more drugs at cancer patients. Here, take this too and this and this and this. Let's get you some skilled nurses at home to help you with some fancy new equipment. Each one adds another triple zero item to your bills.(I could rant on about the annoying part of going to daily radiation for weeks and weeks.)But finally there are two new ideas that are focused on reducing cancer care costs and hospital stays. (Its about time.) Anyway here are the two new ideas:Oncologist Dr Barbara McAneny in Albuquerque, NMlooked at how her cancer patients dealt with hospital stays and ER visits due to low ...
Source: Caroline's Breast Cancer Blog - Category: Cancer & Oncology Tags: cancer care cancer costs hospital Source Type: blogs

Related Links:

ConclusionsA majority of IBC patients in our study presented with node-positive disease, and for those presenting with cN2-3 disease, more extensive axillary surgery is potentially associated with improved survival. For cN0 patients, however, more extensive axillary surgery was not associated with a survival benefit, suggesting an opportunity for more personalized care.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Authors: Batoo S, Bayraktar S, Al-Hattab E, Basu S, Okuno S, Glück S Abstract With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. With the addition of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), improvements in overall survival have been observed among patients with advanced HER2-positive disease. Subsequently, lapatinib, an orally bioavailable small molecule dual HER2- and EGFR/HER1-specific tyrosine kinase inhibitor, received Food and Drug Administration (FDA)...
Source: Journal of Carcinogenesis - Category: Cancer & Oncology Tags: J Carcinog Source Type: research
Publication date: Available online 18 January 2020Source: Redox BiologyAuthor(s): Mohamad Assi, Suzanne Dufresne, Amélie RébillardAbstractIn this paper of the special issue dedicated for the Olympics 2020, we put the light on an exciting facet of exercise-oncology, which may still be unknown to some audience. Accumulating convincing evidences show that exercise reduces cancer progression and recurrence mainly in colon and breast cancer patients. Interestingly, the positive effects of exercise on cancer outcomes were mainly observed when patients practiced vigorous exercise of 6 METs or more. At the molecular ...
Source: Redox Biology - Category: Biology Source Type: research
We describe the adaptation of a model-based design for identifying the maximum tolerated dose combination that efficiently moves from the initial phase in an advanced disease population to the second phase in the target population. Operating characteristics demonstrate the ability of the method to accurately predict true maximum tolerated dose combinations in a high percentage of trials with reasonable sample sizes, while treating participants at and around desirable combinations. The proposed design is a practical, early-phase, adaptive method for use with drug combination dose finding in the presence of shifting patient ...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Contemp Clin Trials Commun Source Type: research
CONCLUSION: SM bioenergetics and oxidative capacity in response to PFE are not impaired following anthracycline treatment. Abnormal SM composition (increased thigh and lower leg IMF-to-SM ratio) may be an important contributor to reduced peak VO2 during whole-body exercise among anthracycline-treated BC survivors. IMPLICATIONS FOR PRACTICE: Peak oxygen consumption (peak VO2 ) is reduced in breast cancer (BC) survivors and is prognostic of increased risk of cardiovascular disease-related and all-cause mortality. Results of this study demonstrated that in the presence of deficits in peak VO2 1 year after anthracycline t...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Abstract BACKGROUND: In the absence of randomized controlled trials, real-world evidence may aid practitioners in optimizing the selection of therapy for patients with cancer. The study's aim was to determine real-word use, as well as compare effectiveness, of single-agent and combination chemotherapy as palliative treatment for female patients with metastatic breast cancer (mBC). MATERIALS AND METHODS: Using administrative claims data from the Symphony Health's Integrated Oncology Dataverse, female patients with mBC treated with at least one chemotherapy-only treatment (COT) between January 1, 2013, and Dece...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
We present the results of a phase I study of an oral selective gamma secretase (GS) inhibitor (critical to Notch signaling), RO4929097 in combination with neoadjuvant chemotherapy for operable triple negative breast cancer. The primary objective was to determine the maximum tolerated dose (MTD) of RO4929097. Secondary objectives were to determine real-time pharmacokinetics of RO4929097 and paclitaxel, safety and pathologic (pCR) complete response to study treatment. Eligible patients, initiated carboplatin at AUC 6 administered intravenously (IV) on day 1, weekly paclitaxel at 80  mg/m2 IV and RO4929097 10 mg dai...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
Conclusions Sentinel lymph node identification using preoperative scintigraphy and intraoperative use of gamma probe seems to be a feasible and efficient method in terms of differentiating patients that require axillary lymph node dissection during breast cancer surgery, even when they have received neoadjuvant chemotherapy. Further large prospective studies allowing subgroup analyses are warranted.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
This study was designed to investigate the role and therapeutic implications of miR-151-5p in breast cancer. The results of the present study revealed that miR-151-5p is significantly downregulated in breast cancer tissues and cell lines. Overexpression of miR-151-5p in SK-BR-3 and CAMA-1 cells inhibits their proliferation and colony formation. Wound heal and transwell assays showed that miR-151-5p inhibits the migration and invasion of the SK-BR-3 and CAMA-1 breast cancer cells. TargetScan analysis followed by the dual luciferase assay confirmed SOCS5 to be the target of miR-151-5p in breast cancer. The expression of SOCS...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
AbstractBackgroundThe aim of the study was to develop a deep learning (DL) algorithm to evaluate the pathological complete response (pCR) to neoadjuvant chemotherapy in breast cancer.MethodsA total of 302 breast cancer patients in this retrospective study were randomly divided into a training set (n =  244) and a validation set (n = 58). Tumor regions were manually delineated on each slice by two expert radiologists on enhanced T1 ‐weighted images. Pathological results were used as ground truth. Deep learning network contained five repetitions of convolution and max‐pooling layers and ended with three dense laye...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
More News: Accidents | Blogging | Breast Cancer | Cancer | Cancer & Oncology | Centers for Medicare and Medicaid Services (CMS) | Chemotherapy | Emergency Medicine | Hospital Management | Hospitals | Medicaid | Medicare | Nurses | Nursing